Clinical remission in patients with asthma treated with twice-yearly depemokimab in the Phase III SWIFT-1/2 studies

Background: Durable clinical remission (CR) is a long-term asthma treatment goal. Depemokimab is the first ultra-long-acting biologic with enhanced IL-5 binding affinity, high potency, and extended half-life, enabling twice-yearly dosing in patients with asthma. In SWIFT-1/2, depemokimab significantly reduced exacerbations in patients with type 2 asthma (characterised by high blood eosinophils). Aim: To assess CR in SWIFT-1/2. Methods: CR was assessed for depemokimab (100 mg subcutaneous every 26 weeks) vs placebo at Week 52 in patients with asthma in SWIFT-1/2. CR was defined by 4 criteria: no exacerbations over 52 weeks; no maintenance OCS in last 90 days; ACQ-5 score≤1.5 and change from baseline in FEV 1 ≥0 mL among the pooled population (pre-specified) and asthma disease duration subgroups (post hoc). Results: The observed proportion of patients meeting CR criteria at Week 52 was greater with depemokimab (29%) vs placebo (23%). The largest proportion that achieved CR was the depemokimab subgroup with asthma